Grazoprevir-Elbasvir Combination Therapy for Treatment-Naive Cirrhotic and Noncirrhotic Patients With Chronic Hepatitis C Virus Genotype 1, 4, or 6 Infection: A Randomized Trial.
about
Spotlight on grazoprevir-elbasvir once-daily combination and its potential in the treatment of hepatitis CAntiviral Therapy in Patients with Viral Hepatitis and Hepatocellular Carcinoma: Indications and PrognosisElbasvir/Grazoprevir: A Review of the Latest Agent in the Fight against Hepatitis CSafety and efficacy of daclatasvir in the management of patients with chronic hepatitis CInterferon-Free Treatments for Chronic Hepatitis C Genotype 1 InfectionNext Steps Toward Eradication of Hepatitis C in the Era of Direct Acting AntiviralsRecent Advances in Antiviral Therapy for Chronic Hepatitis CRecent advances in managing chronic HCV infection: focus on therapy in patients with severe liver diseaseNew approaches in the treatment of hepatitis CStrategies for treating chronic HCV infection in patients with cirrhosis: latest evidence and clinical outcomesHepatitis C Virus Treatment: Is It Possible To Cure All Hepatitis C Virus Patients?Approved Antiviral Drugs over the Past 50 YearsTherapy with Direct-Acting Antiviral Agents for Hepatitis C-Related Liver CirrhosisConcise review: Interferon-free treatment of hepatitis C virus-associated cirrhosis and liver graft infectionDirect-acting antivirals for the treatment of chronic hepatitis C in patients with chronic kidney diseasePrevention of Hepatocellular CarcinomaClinical Laboratory Testing in the Era of Directly Acting Antiviral Therapies for Hepatitis CThe new era of hepatitis C virus therapyInterferon-free combination therapies for the treatment of hepatitis C: current insightsTreatment optimization for HIV/HCV co-infected patients.Hepatitis C virus infection.Global epidemiology and burden of HCV infection and HCV-related disease.Hepatitis C treatment: where are we now?HCV Council--critical appraisal of data: recommendations for clinical practice in a rapidly evolving therapeutic landscapeInvestigational direct-acting antivirals in hepatitis C treatment: the latest drugs in clinical development.Real-World Efficacy of Daclatasvir and Sofosbuvir, With and Without Ribavirin, in HIV/HCV Coinfected Patients With Advanced Liver Disease in a French Early Access Cohort.New Therapies for Hepatitis C Virus Infection.Hepatitis C in a New Era: A Review of Current TherapiesLow frequency of NS5A relevant resistance-associated substitutions to Elbasvir among hepatitis C virus genotype 1a in Spain: a cross-sectional study.Medical and Behavioral Approaches to Engage People Who Inject Drugs Into Care for Hepatitis C Virus Infection.Direct-acting antivirals for the treatment of hepatitis C virus infection: optimizing current IFN-free treatment and future perspectives.Grazoprevir, Elbasvir, and Ribavirin for Chronic Hepatitis C Virus Genotype 1 Infection After Failure of Pegylated Interferon and Ribavirin With an Earlier-Generation Protease Inhibitor: Final 24-Week Results From C-SALVAGE.Elbasvir/Grazoprevir: First Global Approval.Systematic review: current concepts and challenges for the direct-acting antiviral era in hepatitis C cirrhosis.Direct-acting antivirals for chronic hepatitis C.Comparison of Three Different Hepatitis C Virus Genotyping Methods: 5'NCR PCR-RFLP, Core Type-Specific PCR, and NS5b Sequencing in a Tertiary Care Hospital in South India.Susceptibilities of genotype 1a, 1b, and 3 hepatitis C virus variants to the NS5A inhibitor elbasvir.Sofosbuvir in Combination with Simeprevir +/- Ribavirin in Genotype 4 Hepatitis C Patients with Advanced Fibrosis or Cirrhosis: A Real-World Experience from BelgiumSubstitutions at NS3 Residue 155, 156, or 168 of Hepatitis C Virus Genotypes 2 to 6 Induce Complex Patterns of Protease Inhibitor ResistanceTreatment of hepatitis C virus infection for adults and children: Updated Swedish consensus recommendations.
P2860
Q26740233-F36B89F7-7199-4DF2-B06C-E292C95AB511Q26740313-425C7FCA-7EA3-41D2-8CA4-C38A61DFE586Q26741123-6E4F937C-3476-48C6-8557-3DA057FA0EADQ26745769-E7A5FF01-99ED-4C25-B8F0-9E4B5DC530BFQ26746563-2FA3BC37-DF1D-4B97-866C-9BE3EA92FAD1Q26747561-DE714BB4-0F53-4543-88FD-5181C381A2CEQ26750476-9D311632-997C-4A6A-98FE-27B366455893Q26752433-18F2738C-0BED-46FD-964D-1790611E5523Q26773271-E987030F-4F07-4EC1-BA45-6D76AF05A48FQ26777086-6867D04D-D90A-46BD-AD34-F6281BDD3F93Q26801828-571F1D70-EC91-496C-8B4F-2C3C91A6EE7FQ27755387-0296FE53-EE5F-4CA8-A726-B440DE1E9DDCQ28070260-0226E10B-7AB2-48DA-8E9A-3FCB248A2543Q28075544-65DCE2B9-12E8-4DAA-93A3-12D6573B12A2Q28077263-EC5A4A83-2D43-4445-8358-E1B9CADEACACQ28079576-F1AEBBCA-58A9-4938-9A76-621DDC67C66BQ28080225-F876F2A8-118E-4750-B60F-6480AA12617FQ28086947-0F75B752-9604-4230-BDFD-35D6A53EF3ABQ28087400-FEC263FF-73A2-462B-BF8E-A870BC8F040CQ30235034-45F281F4-2990-4BCA-A536-FBEA7B37F9ACQ30235491-770B748A-6929-40BB-A1BC-D05C8353E590Q30240220-3CFCDC3A-C03D-4AD1-A35E-B82D893B4E53Q30378509-C8FDCC20-8291-46C1-A3F7-C550D8B4B1E8Q31012317-64DF7D85-DB86-4640-B96A-A032AC4EA311Q31051529-69C4A623-675F-4550-B03B-EA3368D50FBCQ33557819-A9D93837-3CB4-47C5-9DA5-94E406793DF5Q33560181-BF6B4FEE-A79B-45B0-BFA5-6FBFB89068BAQ33585021-CC5EE4C5-6250-4758-9732-D268A276BBB5Q33767618-62D33E35-6EB6-4B36-B4BE-0611A92DE2B0Q33853664-89610D2A-4FE2-4424-85B9-AD4EFC25087FQ34045760-8D64E9F1-45F8-4736-A519-91152F0E3B23Q34494173-9CB36563-D4F9-49C4-8B32-FA2B57ADA1B6Q34516975-D382A692-3D9E-420D-9C0B-8DE56A5B8643Q34522481-26E4FC71-A259-4283-84D9-2131DCE266D6Q34557595-5F40218C-2DA4-43FB-8AC2-36270D38476BQ36118779-64289E5D-BBFD-44B3-9468-3370E11ADAF9Q36158391-F6D51C17-3EE9-430A-B7AA-A3E3081F496BQ36261373-E81913FB-D1A4-4715-8155-70851E80560CQ36290778-5ABDA4DB-E57E-4C9F-B728-B76ADBE28D5EQ36519126-B1826E3F-F90D-4CDA-9E7C-278E3412515C
P2860
Grazoprevir-Elbasvir Combination Therapy for Treatment-Naive Cirrhotic and Noncirrhotic Patients With Chronic Hepatitis C Virus Genotype 1, 4, or 6 Infection: A Randomized Trial.
description
2015 nî lūn-bûn
@nan
2015年の論文
@ja
2015年学术文章
@wuu
2015年学术文章
@zh-cn
2015年学术文章
@zh-hans
2015年学术文章
@zh-my
2015年学术文章
@zh-sg
2015年學術文章
@yue
2015年學術文章
@zh
2015年學術文章
@zh-hant
name
Grazoprevir-Elbasvir Combinati ...... Infection: A Randomized Trial.
@en
type
label
Grazoprevir-Elbasvir Combinati ...... Infection: A Randomized Trial.
@en
prefLabel
Grazoprevir-Elbasvir Combinati ...... Infection: A Randomized Trial.
@en
P2093
P356
P1476
Grazoprevir-Elbasvir Combinati ...... Infection: A Randomized Trial.
@en
P2093
Bach-Yen Nguyen
Deborah D Brown
Eliav Barr
Janice Wahl
Joan R Butterton
Mark J DiNubile
Michael N Robertson
Paul J Pockros
Reem Ghalib
Shuyan Wan
P356
10.7326/M15-0785
P407
P577
2015-07-01T00:00:00Z